BeiGene Starts Global Phase III Trial of BTK Inhibitor

BeiGene has started a global Phase III trial of its lead molecule, BGB-3111, a Bruton's tyrosine kinase (BTK) inhibitor. The candidate will be administered to patients with Waldenström’s macroglobulinemia. WM is a rare disease, though ultimately BeiGene will seek approval of BGB-3111 for other forms of lymphoma. In the trial, BeiGene's candidate will be compared to Imbruvica, an already approved drug. BeiGene believes BGB-3111 will prove to have a better side effect profile than Imbruvica because it is more selective. In earlier trials, BGB-3111 showed a partial response rate of 34%, which the company called "very good." More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //